Coya Therapeutics, Inc. · NASDAQ:COYA
Coya Therapeutics — Investor Presentation (August 2026)
25 slides from Coya Therapeutics's investor presentation, August 2026
Slide 1: Combating Neurodegeneration Via Treg-Directed Combination Therapy
INVESTOR OVERVIEW I AUGUST 2026 Combating Neurodegeneration Via Treg-Directed Combination Therapy
Slide 2: Cautionary Note of Forward-Looking Statements and Disclaimers
Cautionary Note of Forward-Looking Statements and Disclaimers in this Presentation This presentation and the accompanying oral presentation contain “forward-looking” statements that are based on our management’s beliefs and assumptions and on information currently available to management. Forward- l
Slide 3: Coya Therapeutics (COYA): Investment Highlights
Focused Anti-Neurodegenerative Pipeline › COYA 302 (Low Dose IL-2 + CTLA4-Ig): A pipeline in a product across ALS, FTD, AD, Parkinson’s Disease. COYA 303 (Low Dose IL-2 + GLP-1 RA): Alzheimer’s Disease Near-Term COYA-302 ALS Data Readout Q1 2027 › ALSTARS Phase 2 enrollment completion expected H2 20
Slide 4: LD IL-2 Combination Therapy: Pillars For Success
LD IL-2 Combination Therapy: 3 Pillars For Success The neurodegeneration field increasingly recognizes combination-based therapeutic strategies such as Coya's as a viable path forward for diseases driven by complex, multifactorial biology Differentiated Combination-based Validated Science Early Clin
Slide 5: COYA Targets T-Regs Role in Inflammation
COYA Targets T-Regs Role in Inflammation Tregs are specialized immune cells that help maintain a balanced immune system 1 3 T-reg dysfunction leads to T-regCOYA’s dysfunction leads therapeutics to synergistically immune activation and expand dysfunctional Tregs and shift immune activation and them t
Slide 6: ALS and FTD Market Opportunity
ALS and FTD Market Opportunity Two orphan diseases with short life expectancy from diagnosis and significant loss of quality of life Amyotrophic Lateral Sclerosis ALS Frontotemporal Dementia FTD Patient Population & Unmet Need Patient Population & Unmet Need ~33,000 patients in U.S. (NIH) 50,000–60,
Slide 7: COYA in ALS
THERAPEUTICS COYA 302 in ALS
Slide 8: ALS: An Urgent Need for New Treatment Options
ALS: An Urgent Need for New Treatment Options ALS is a progressive disease that attacks the motor neurons in the brain and spinal cord that control voluntary muscles — including those needed to speak, swallow, and breathe1 20–30% 90% die within two years of diagnosis, develop “sporadic” ALS with no
Slide 9: Approved Therapies Show Only a Modest Treatment Effect
Approved Therapies Show Only a Modest Treatment Effect PRO-ACT ALS Database Mean (SD) RELYVRIO and RADICAVA Mean Change vs. Documented Decline (ALSFRS-R) Placebo on ALSFRS-R at Week 24 2 3 Baseline 4 8 12 16 20 24 Weeks In the natural history of ALS, patients average a ~1 Both approved therapies slo
Slide 10: LD IL-2 + CTLA4-Ig IIT: Compelling Signal in Mild-to-Moderate ALS
LD IL-2 + CTLA4-Ig IIT: Compelling Signal in Mild-to-Moderate ALS1 ALSFRS-R improved or stabilized LD IL-2 + CTLA-4 Ig ameliorates progression in a over 6 months 48-week IST in ALS Patients Mean (±SD) ALSFRS-R Score (N=4) 48 44 32 30 33.5 33.75 40 36 ALSFRS-R Score 32 28 24 20 16 12 48-Week Treatmen
Slide 11: COYA 302: ALSTARS Phase 2 Study in ALS Ongoing
COYA 302: ALSTARS Phase 2 Study in ALS Ongoing Key Inclusion Criteria Randomized, Double-Blind, Placebo-Controlled Phase 2 Study with Blinded Active Extension • Diagnosis of sporadic or familial ALS 24 wk. Double Blind 24 wk. Blinded Active Extension 4 wk. Screening Treatment Phase Phase • ALSFR-R s
Slide 12: ALS Summary
ALS Summary ＋ ＋ ＋ ＋ The Disease & Early Clinical COYA 302: Market Unmet Need Signal Coya's Approach Opportunity Rapidly fatal — ~1- 48-week investigator- Low-dose IL-2 + CTLA4-Ig Orphan indications with point/month ALSFRS-R initiated study in mild-to- combination therapy high unmet need decline; 20–
Slide 13: COYA in FTD
THERAPEUTICS COYA 302 in FTD
Slide 14: LD IL-2 & CTLA-4 Ig: Signal in Mild-to-Moderate FTD
LD IL-2 & CTLA-4 Ig: Signal in Mild-to-Moderate FTD Encouraging clinical data in FTD in Investigator Sponsored Study (n=9) Treg suppressive function and percentage: (1) Increased after first treatment (2) Remained elevated across 22-week treatment period Increased Treg Suppressive Function Expansion
Slide 15: LD IL-2 & CTLA-4 Ig: Signal in FTD – cont.
LD IL-2 & CTLA-4 Ig: Signal in FTD – cont. Cognitive Stability in 22-Week Investigator Sponsored Study CDR‐FTLD, MoCA, PASS cognitive tests exhibited no cognitive decline at end of study compared with baseline Moca Scores Remain Unchanged CDR-FTLD Scores Remains Unchanged Compared to Baseline Compar
Slide 16: COYA-302 in FTD: Phase 2a Expected 2H 2026 Start
COYA-302 in FTD: Phase 2a Expected 2H 2026 Start Randomized, Double-Blind, Placebo-Controlled Phase Key Inclusion 2a Proof-of-Concept Study Criteria 4 wk. Screening 52-Week Double Blind Treatment Phase • Non-Fluent Primary Progressive Aphasia Subtype COYA 302 (N=32) • Global Clinical Dementia Rating
Slide 17: FTD Summary
FTD Summary ＋ ＋ ＋ ＋ The Disease & Early Clinical Signal COYA 302: Market Unmet Need 22-week investigator- Coya's Approach Opportunity sponsored study in mild-to- Frontotemporal dementia Low-dose IL-2 + CTLA4-Ig Orphan indication with moderate FTD (n=9) (FTD) — progressive combination therapy high un
Slide 18: COYA in AD
THERAPEUTICS COYA 3021in AD
Slide 19: COYA in Alzheimer's: Compelling Preclinical Signal
COYA 303 in Alzheimer's: Compelling Preclinical Signal COYA-303: Encouraging in-vitro data and in LPS mouse model • Lipopolysaccharide (LPS) mouse model is an established murine model of systemic and neuro- Reduced peripheral pro- inflammation • COYA 303 decreased both peripheral inflammation and in
Slide 20: Financial Summary and Dr. Reddy's Collaboration
Financial Summary and Dr. Reddy’s Collaboration Financial Summary Dr. Reddy’s Collaboration As of June 30, 2026 Announced December 2023 Cash: $43.2 million Dr. Reddy’s gets: Greenlight Capital: 9.9% ownership* An exclusive license to commercialize COYA 302 for ALS in the US, Canada, the EU and UK, i
Slide 21: Multi-Layered IP Protection
Multi-Layered IP Protection Formulation Combination Biomarker Regulatory Granted patent on low- Patent on combinations of Biomarker IP for 302 in ALS and FTD are orphan dose IL-2 aqueous any IL-2 (including long- ALS provides an diseases — potential 7 formulation — enables at- acting) with any CTLA-
Slide 22: Key Catalysts and Milestones
Key Catalysts and Milestones Complete enrollment: expected 2H 2026 COYA 302 in ALS: Topline data: expected 1Q 2027 ALSTARS (Phase 2) Management to provide periodic updates IND accepted in 1Q 2026 COYA 302 in FTD: Phase 2 study: expected initiation 2H 2026 Present further translational and clinical d
Slide 23: Management and Board
Board of Directors Management and Board Mark Pavao, M.B.A. Managing Partner Biotech Value Advisors Ann Lee, Ph.D. Chief Technical Officer Prime Medicine Dov Goldstein, M.D., MBA Arun Swaminathan, Ph.D. Fred Grossman, D.O., FAPA David Snyder Chief Financial Officer Chief Executive President & Chief F
Slide 24: Scientific Advisors Board
Scientific Advisors Board Shimon Sakaguchi, Clive Svendsen, Malcolm Brenner, Stanley Appel, M.D., Ph.D. Ph.D. M.D., Ph.D. M.D. Member of the National Academy of Director, Cedars-Sinai Regenerative Director, Center for Cell and Gene Co-Director, Houston Methodist Sciences Medicine Institute Therapy N
Slide 25: Thank You
Thank You INVESTOR OVERVIEW I AUGUST 2026
Coya Therapeutics — Investor Presentation (August 2026) on 6ix